Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Alliance Global Partners analyst James Molloy downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Neutral.
Maxim Group analyst Naz Rahman downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Hold.
HC Wainwright & Co. analyst Yi Chen downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Neutral and maintains $6 price...
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per s...
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("...
HC Wainwright & Co. analyst Yi Chen reiterates Alimera Sciences (NASDAQ:ALIM) with a Buy and maintains $6 price target.
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(...
